TRAVERE THERAPEUTICS, INC. Proceeds from Lines of Credit
TRAVERE THERAPEUTICS, INC. (TVTX) reported Proceeds from Lines of Credit of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2017-03-01
- TRAVERE THERAPEUTICS, INC. proceeds from lines of credit for the quarter ending 2015-12-31 was $0.00.
- TRAVERE THERAPEUTICS, INC. proceeds from lines of credit for the quarter ending 2014-12-31 was $0.00.
- TRAVERE THERAPEUTICS, INC. proceeds from lines of credit for the quarter ending 2014-09-30 was $3.61M.
- TRAVERE THERAPEUTICS, INC. proceeds from lines of credit for fiscal 2016 was $0.00.
- TRAVERE THERAPEUTICS, INC. proceeds from lines of credit for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- TRAVERE THERAPEUTICS, INC. proceeds from lines of credit for fiscal 2014 was $42.37M.
- TRAVERE THERAPEUTICS, INC. proceeds from lines of credit for fiscal 2013 was $0.00.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-03-01 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $0.00 10-K · filed 2017-03-01 | ||
| 2015-09-30 | $0.00 10-Q · filed 2015-11-06 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $3.61M derived: sum of 2 quarters · filed 2017-03-01 | $42.37M 10-K · filed 2017-03-01 | |
| 2014-09-30 | $3.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $42.37M 10-Q · filed 2015-11-06 | ||
| 2014-06-30 | $38.75M 10-Q · filed 2015-08-10 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |